MDxHealth SA is a precision diagnostics company headquartered in Herstal, Belgium, that develops and commercializes urologic testing solutions. The company operates a portfolio of non-invasive and tissue-based tests designed to improve prostate cancer detection and management. Select mdx is a urine-based test measuring mRNA biomarkers to aid prostate cancer diagnosis, while Confirm mdx analyzes tissue samples to detect occult cancer in previously negative biopsies. The company also offers Resolve mdx, a urinary tract infection test that identifies personalized antibiotic sensitivities, and Genomic Prostate Score, which provides genomic insights for prostate cancer treatment navigation.
The company distributes its products primarily through a dedicated urology sales force in the United States, with additional commercial operations across Europe and internationally. MDxHealth maintains a collaboration with the University of Oxford regarding the Genomic Prostate Score testing in the ProtecT trial, a landmark prostate cancer research study. The company was incorporated in 2003 and operates under its current name following a rebranding from OncoMethylome Sciences SA in 2010.
No 10-K filings found.